International experts update CAR T-cell therapy guidelines for severe autoimmune diseases

An international group of 31 experts has released updated guidelines to help medical professionals use CAR T-cell therapy for patients with severe autoimmune diseases that do not respond to conventional treatments.

CAR T-cell therapy, typically used to treat certain cancers, involves modifying a patient’s immune cells to target specific disease markers. The new framework addresses its potential application in autoimmune conditions where standard therapies have failed.

The updated consensus highlights the need for careful patient selection, monitoring, and long-term follow-up due to the complexity and risks associated with this advanced treatment approach.

Experts from diverse fields, including immunology and rheumatology, collaborated to develop these recommendations, emphasizing the importance of balancing innovation with patient safety.

Based on reporting from Medical Xpress (Cancer).

Source: Medical Xpress (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.